◾ The CANA Phase 3 programme included a series of clinical trials evaluating CANA in T2DM in different positioning along the patient pathway. Evidence on efficacy and safety from direct comparisons were used when possible ◾ Patient baseline characteristics were taken from the relevant CANA trial in that setting. Treatment effects also came from these trials where possible ◾ For the comparison of CANA 100 mg with SITA in triple therapy, treatment effects were taken from the results of a network meta-analysis (NMA; Pacou et al 21 and data on file) since direct comparisons were not available ( Table 1) ◾ HbA1c and SBP progressed for each patient according to UKPDS 68. 22 Lipid values progressed according to the equations from the Framingham Heart Study. 23 BMI progression was conservatively assumed to be flat. The risk of cardiovascular complications was obtained using the UKPDS Outcomes Model 22 ◾ In the model, patients discontinued treatment when a trial-related HbA1c threshold of 7.5% was reached, at which point they switched to insulin at a dose of 40 IU/day ◾ AEs included in the model were urinary tract infections and genital mycotic infections -In the CANA studies, rates of urinary tract infections were generally similar across groups; there was a higher incidence of genital mycotic infections with CANA versus comparator treatments ◾ Hypoglycaemia events were included as severe and non-severe in the model ◾ Interim life tables for Portugal were calculated from the Portuguese cause of death and population data obtained from the National Statistical Institute of Portugal (INE; data on file), adjusting Portuguese all-cause mortality tables to exclude causes of death related to diabetes ◾ In the model, it was assumed that 65% of patients were treated with CANA 100 mg and 35% of patients were treated with CANA 300 mg
Economic Inputs
◾ The annual costs of comparator drugs were based on the daily dose tested in the clinical trials. The public prices of each pack were specified as those relevant to INFARMED 24 ◾ Costs of managing and treating diabetes-related complications in Portugal were derived from published sources and are shown in Table 2 ◾ CDM calculates indirect costs in relation to fatal events and non-fatal events. The indirect costs associated with productivity loss were included in the base case analyses and were calculated as a function of retirement age, mean salary of males and females (adjusted for employment rates), and average number of working days ◾ For T2DM and its complications, health state utilities for the model were derived, wherever possible, from the UKPDS 25 and supplemented with data from other sources as necessary ◾ Cost and health benefits were discounted at 5%. 28 Lifelong perspective is relevant for modelling chronic conditions. At an average age at baseline of 55 to 57 years, the life expectancy in Portugal is approximately 30 years, which was used in this analysis ◾ A weighted average of 65:35 was applied in the cost-effectiveness analysis. According to the SmPC, 29 the starting dose of CANA is 100 mg. The weighted average reflects the opportunity for dose escalation with CANA as the disease progresses, and further therapy intensification is needed to control HbA1c; dose escalation is not possible with SITA
RESULTS
◾ The cost-effectiveness analyses indicated that CANA (100 and 300 mg, with a weighted average of 65:35) is dominant in comparison with SITA 100 mg in dual therapy as add-on to MET, and in triple therapy as add-on to MET plus SU ( Table 3 ) ◾ In dual therapy as add-on to MET, CANA (100 and 300 mg, with a weighted average of 65:35) had an average cost savings of €24 and an average quality-adjusted life year (QALY) gain of 0.036. In triple therapy as add-on to MET plus SU, CANA (100 and 300 mg, with a weighted average of 65:35) had an average cost savings of €171 and an average QALY gain of 0.033 ◾ Sensitivity analyses suggested that CANA is also cost-effective from a payer perspective and when the time horizon, which is 30 years in the base case, is reduced to 10 years (data not shown)
◾ The cost-effectiveness planes are shown in Figure 2 . The cost-effectiveness planes are concentrated in the southeast quadrant where CANA dominates. The cost-effectiveness acceptability curves are shown in Figure 3 , and indicate that the probability of CANA being cost-effective is more than 50% for a willingness-to-pay threshold of at least €20,000 per QALY in each comparison
CONCLUSION
◾ Using CANA, as opposed to SITA, for dual and triple therapy (add-on to MET or add-on to MET plus SU) was estimated to result in cost offsets and increases in QALYs ◾ These analyses suggest that using CANA versus SITA is likely to be a cost-effective option for patients needing additional glucose control in Portugal BMI, body mass index; SBP, systolic blood pressure; SE, standard error. *Mean change ± SE from baseline. †Event rate per 100 patient-years. ‡Not reported in the NMA, assumed to be the same as CANA 100 mg. Triple therapy
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